SAN DIEGO, May 2, 2022 /PRNewswire/ — Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with severe neuromuscular and neurodegenerative diseases, today announced that new data from preclinical research of its proprietary CORRECTx™ platform in…
Locanabio to Present New Preclinical Data Demonstrating Application of CORRECTx™ Platform for Treating Amyotrophic Lateral Sclerosis at American Society of Gene and Cell Therapy 25th Annual Meeting
